European University to Fund Core One Labs Akome Advanced Neurogenesis Stimulation Studies

News and research before you hear about it on CNBC and others. Claim your one week free trial for StreetInsider Premium here.

VANCOUVER, BC /ACCESSWIRE/October 14, 2022/ Core One Labs Inc. (CSE: COOL)(OTCQB: CLABF)(Frankfurt: LD6)(WKN: A3CSSU) (there “Company” Where “core one“), following its August 18, 2022 press release, is delighted to announce its wholly owned subsidiary, Akome Biotech Ltd. (“Akome“), the Company’s biopharmaceutical research and development division focused on the discovery and development of novel psychedelic drugs targeting neurological and mental disorders, is finalizing discussions with Complutense University of Madrid (“Universidad Complutense”) to fund and initiate the advancement of its neurogenesis stimulation studies (“neurogenesis studies“) relating to the effectiveness of its specific plant bioactives (“bioactive compounds) which are part of their patent pending psychedelic drug formulations. The Universidad Complutense has expressed strong interest in advancing the studies to the next stage and will provide funding to complete the studies, with Akome only required to provide the raw materials.

As stated in the company’s August 18, 2022 press release, neurogenesis studies conducted by Universidad Complutense provide very encouraging results, having revealed that the bioactive compounds selected by Akome induce remarkable neurogenetic activity in controlled tests. Moreover, studies strongly suggest that each of the Bioactive compounds selected by Akome have significant potential to elicit therapeutic activity against various neurological conditions and could have therapeutic effects in more than one targeted disease.

Following the encouraging results of the studies, Akome and Dr. Jose A. Morales-Garcia, professor at Complutense University and member of the Center for Networked Biomedical Research in Neurodegenerative Diseases (CIBERNED) at the Carlos III Health Institute , have initiated discussions and are currently mapping advanced models of neurogenesis. Goals for the next stage of the program include testing all of Akome’s bioactive compounds in combination with selected psychedelic compounds; define potential pharmacodynamics; as well as to help design the next set of studies to demonstrate beneficial effects in animal models of neurological diseases and mental health conditions.

The results of the initial study were very promising, and Universidad Complutense looks forward to moving forward with the next steps in this trial and has offered to provide the necessary funding to conduct the research,” Core One CEO Joel Shaker commented. “The continuation of this advanced neurogenesis study in partnership with Universidad Complutense marks another important milestone in the company’s drug development pipeline. »

“Universidad Complutense’s expressed commitment to moving forward with advanced neurogenesis studies is a welcome vote of confidence at this point in our drug development process and marks another important milestone and their potential for success. .”

About Core One Labs Inc.

Core One Labs is a life science biotechnology research and development company focused on bringing psychedelic drugs to market through the development and production of psychedelic compounds, the advancement of psychedelic-assisted treatments, and the the integration of new technologies of administration systems.

The company has a multi-faceted business approach and integrates multiple business lines and complementary units to establish itself as an industry leader in the emerging and rapidly growing psychedelics market.

Core One, through its wholly owned subsidiary Vocan Biotechnologies Inc., has developed and filed a patent application for a proprietary psilocybin production system using engineered bacteria. It also holds 4 provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental disorders, under its wholly owned subsidiary Akome Biotech Ltd., and 3 provisional patents under its other wholly owned subsidiary , Awakened Biosciences. Inc., for additional synthetic technologies for psilocybin and psilocin production methods.

In addition to the development of psychedelics and psychedelic compounds, Core One has interests in four medical clinics that maintain a combined database of over 275,000 patients. Through its clinics, the Company intends to integrate a deployment of its intellectual property related to psychedelic technologies and to participate in the advancement of psychedelic-based treatments for mental health disorders.

Core One Labs Inc.

Joel Shacker
Chief executive officer


[email protected]


The Canadian Securities Exchange has not reviewed and accepts no responsibility for the adequacy or accuracy of the content of this press release.

The information in this press release contains forward-looking statements based on assumptions as of the date of this press release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain and that actual performance may be affected by a number of important factors, many of which are beyond the Company’s control. These factors include, among others: the risks and uncertainties associated with the Company’s limited operating history and the need to comply with stringent regulatory regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied by the forward-looking information. Except as required by applicable securities laws, the Company undertakes no obligation to publicly update or revise any forward-looking information.

In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offense to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One has no direct or indirect involvement in the illegal sale, production or distribution of psychedelic substances in the jurisdictions in which it operates. Although Core One believes that psychedelics can be used to treat certain medical conditions, it does not advocate the legalization of psychedelics for recreational use. Core One does not deal with psychedelics except in laboratory and clinical trials conducted under approved regulatory frameworks.

THE SOURCE: Core One Labs Inc.

See the source version on

Margie D. Carlisle